

"LANG et al.

U.S. National Phase of PCT/FR00/02443

U.S. Serial No. Unknown

12. (Amended) Lymphocyte populations which have been selected and, where appropriate, amplified, characterized in that they are made up exclusively of T lymphocytes which are reactive towards the peptide of a complex with multimers according to claim 6.


REMARKS

Claims 1-13 are pending. The claims have been amended to delete multiple dependencies, without prejudice. An early and favorable Action on the merits is requested.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff
Reg. No. 36,663

BJS:ms
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADE**IN THE CLAIMS**

3[/. (Amended) Multimers according to claim 1 [or 2], characterized in that the modification corresponds to a mutation in the $\alpha 3$ domain of at least one amino acid, with respect to the corresponding domain of a native heavy chain capable of binding to the said CD8 co-receptor.

4[/. (Amended) Multimers according to claim 1 [or 2], characterized in that the modification corresponds to chemical modification of at least one amino acid of the $\alpha 3$ domain of a heavy chain, with respect to the corresponding domain of a native heavy chain capable of binding to the said CD8 co-receptor.

5[/. (Amended) Multimers according to claim 1 [or 2], characterized in that the modification corresponds to the deletion of at least one amino acid of the $\alpha 3$ domain of a heavy chain, with respect to the corresponding domain of a native heavy chain capable of binding to the said CD8 co-receptor.

6[/. (Amended) Multimers according to [any one of claims 1 to 5] claim 1, characterized in that they are in the form of complexes with antigenic peptides.

8[/. (Amended) Use of multimers according to claim 6 [or 7] for the purpose of detection and/or isolation of peptide-specific CD8+ T lymphocyte populations.

10[/. (Amended) Method for the detection of peptide-specific CD8+ T lymphocyte populations from a polyclonal population, characterized in that it comprises:

- bringing the polyclonal population into contact with multimers complexed with antigenic peptides according to claim 6 [or 7] under conditions which allow interaction between the modified class I MHC/peptide complexes and T lymphocyte receptors which have an affinity for the said complexes,

- visualization of the lymphocyte populations which are bound to the said complexes.

11[]. (Amended) Method for isolation of peptide-specific CD8+ T lymphocyte populations from a polyclonal population, characterized in that it comprises:

- bringing the polyclonal population into contact with magnetic beads on which are bound the peptide/class I CMH analogue complexes according to claim 6 [or 7] under conditions which allow interaction between the said complexes and T lymphocyte receptors which have an affinity for the said complexes,

- recovery of the bound populations, the screening operation being repeated, if desired, and/or followed, where appropriate, by a stage

- of *in vitro* amplification of the populations selected.

12[]. (Amended) Lymphocyte populations which have been selected and, where appropriate, amplified, characterized in that they are made up exclusively of T lymphocytes which are reactive towards the peptide of a complex with multimers according to claim 6 [or 7].